OGT Awarded ISO 9001:2008 for its Management Systems
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that the management system at its Oxford, UK Headquarters has been certified to BS EN ISO 9001:2008 by the British Standards Institution (BSI), one of the world’s leading certification bodies. The scope of certification includes the design and provision of OGT’s CytoSure™, Genefficiency™ and biomarker discovery products and services, and demonstrates the company’s commitment to providing the highest quality solutions and customer service.
The ISO 9001:2008 standard promotes a process approach to quality management that focuses on fully meeting customer requirements, measuring customer satisfaction and achieving continual improvement. Dr Mike Evans, OGT’s CEO, commented: “ISO 9001 certification is part of a wider programme of initiatives that we are conducting to gain independent endorsement of our methods. We recently became the first company to be named as a High-Throughput Certified Service Provider for Agilent microarrays, and these initiatives put us at the forefront of the growing genomic research and clinical diagnostic products and services markets. ISO 9001 registration underpins the commitment of our talented and experienced team to designing and providing high quality products and services.”
ISO 9001:2008 certification followed an assessment by BSI, requiring on-site audit and examination of OGT's documented procedures and operations, including product design and development processes. The OGT Management System will subsequently be monitored through OGT’s own internal audit procedures and by periodic surveillance audits by the certification body. For further information on OGT’s products and services, please visit www.ogt.co.uk.
Notes for editors:
About Oxford Gene Technology:
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Find out more
For more information about any OGT product or service, please contact us.